None of the supplied claim-level records report rT3 (or T3, T4, TSH) outcomes for ketogenic diets, so no pooled rT3 effect size can be computed from these sources. Adjacent meta-analytic evidence exists only for serum uric acid (KD MD +0.26 mg/dL, 95% CI -0.47 to 0.98, IΒ² 95.32%; VLCKD subgroup -0.04, IΒ² 0%) , and for fat-free mass, where DXA hydration artifacts (glycogen-water loss) are a key confound relevant to any endocrine outcome measurement . A viable plan: register a PROSPERO protocol, search PubMed/Embase for "ketogenic AND (reverse T3 OR rT3 OR thyroid)", screen RCTs with baseline/endocrine follow-up, extract rT3/T3 ratio with RoB-2, and use random-effects models with pre-specified subgrouping by VLCKD vs LCKD and duration. If zero eligible RCTs exist, report an empty meta-analysis rather than synthesizing mechanistic speculation.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.